Abstract
Artificial intelligence is entering neuroradiology at a moment in which our discipline is already undergoing a profound transformation. Images are becoming more quantitative, diseases are being understood as dynamic biological processes, and clinical decisions increasingly depend on the integration of anatomy, tissue composition, physiology, molecular signals, longitudinal change, and patient-specific risk. In this context, AI should not be seen simply as another technological tool added to the neuroradiologist’s workstation. It represents something deeper: a possible reorganization of how we see, measure, reason, communicate, and take responsibility.
For many years, the conversation around AI in medical imaging has been dominated by performance. We have asked whether algorithms can detect lesions, segment structures, classify diseases, predict outcomes, or match expert readers. These questions were necessary because they helped establish proof of concept and showed that computational systems can extract meaningful information from images at a scale and speed unavailable to human observers. In neuroradiology, this has been particularly relevant for stroke detection, hemorrhage triage, vessel occlusion identification, tumor segmentation, demyelinating lesion quantification, brain volumetry, aneurysm analysis, and many other tasks.
Yet, performance alone is no longer an adequate horizon. An algorithm can be accurate in a curated dataset and still remain fragile in clinical practice, where image quality, comorbidities, atypical presentations, scanner variability, urgency, and incomplete information constantly reshape the problem. The central issue is not only whether a model reaches a high benchmark score, but whether its output can be trusted within the complexity of a real workflow. A system that accelerates reporting but reduces attention, offers a plausible conclusion without revealing uncertainty, or performs well in common cases while failing at the margins of safety does not truly strengthen clinical care. It may instead transfer part of the risk from visible human reasoning to less visible computational behavior. The next phase of AI in neuroradiology will therefore not be defined only by whether systems can provide correct outputs. It will be defined by whether they can be integrated into clinical practice in a way that improves judgment.
This distinction is essential because neuroradiology is not a discipline of image recognition alone, but a discipline of contextual interpretation. Signal intensity, vascular anatomy, perfusion maps, diffusion restriction, enhancement patterns, and volumetric change acquire meaning only when they are connected to symptoms, timing, prior examinations, technical conditions, disease probability, and therapeutic consequence. A brain MRI, a CT angiogram, or a perfusion study does not speak in isolation; each becomes clinically relevant through the relationships the neuroradiologist is able to establish among visible findings, invisible mechanisms, and the patient’s clinical trajectory. The task is therefore not simply to identify an abnormality, but to understand what that abnormality may represent, how reliable that interpretation is, and what decisions may follow from it.
This becomes particularly evident at the margins of clinical decision-making, where imaging findings must be translated into action under conditions of uncertainty. In acute stroke, for example, the detection of a large vessel occlusion, the estimation of infarct core, or the quantification of perfusion mismatch are essential contributions, but they do not exhaust the decision. Time from onset, collateral circulation, infarct evolution, hemorrhagic risk, patient frailty, therapeutic availability, and uncertainty in the clinical history all influence what the image should mean for that patient at that moment. The same principle applies across neuroradiology. In brain tumors, quantitative assessment may describe heterogeneity, but prognosis and treatment response emerge from the interaction between imaging phenotype, molecular profile, surgical strategy, therapy, and longitudinal evolution. In multiple sclerosis, lesion burden is relevant only when interpreted together with lesion location, temporal dissemination, cortical involvement, atrophy, silent progression, and the biological meaning of change. In dementia, atrophy patterns, connectivity alterations, and biomarker information acquire value only when placed within cognitive trajectory, clinical phenotype, and comorbidity. In each case, AI may help extract, quantify, and organize information, but the clinical meaning of that information depends on integration.
The image, in other words, is not the diagnosis. It is a biological surface. Behind the visible abnormality there are mechanisms, trajectories, compensations, and risks that are only partially accessible to observation. One of the most promising contributions of AI may be its ability to help us move from visual description to tissue characterization, from pattern recognition to biological inference, from isolated images to temporal models of disease. This is where AI, quantitative imaging, advanced MRI, photon-counting CT, perfusion imaging, vessel wall imaging, radiomics, and multimodal data integration converge.
However, this promise requires caution. If AI is introduced into neuroradiology merely as a system that delivers conclusions, it may narrow rather than expand the diagnostic process. A suggestion that appears precise but is not accompanied by uncertainty, context, or an intelligible rationale can become a particularly subtle form of black box: not opaque because it is silent, but opaque because it is persuasive. In this setting, the greatest risk is not only that the system may be wrong, but that its wrongness may appear coherent enough to influence the reader before independent interpretation has fully formed. The neuroradiologist may then begin to evaluate the image through the hypothesis offered by the machine, rather than using the machine as one element within a broader act of clinical reasoning. Automation bias, in this sense, is not simply passive acceptance of an AI output; it is the gradual displacement of the starting point of interpretation.
For this reason, explainability should not be understood only as a technical property. It is a clinical interface. A useful AI system should not simply tell the neuroradiologist what it thinks the diagnosis is. It should help show which image features were relevant, what alternative interpretations remain possible, where uncertainty is high, what information is missing, and whether the case lies outside the conditions in which the model is reliable. In complex neuroradiology, a good explanation is not a decorative addition to an output, it is part of safety.
Uncertainty is part of the same problem. Neuroradiology is often practiced in conditions in which diagnoses are incomplete, findings are ambiguous, disease is evolving, and the available information is fragmentary. In such circumstances, the most responsible interpretation is not always the most definitive one. It may be the one that recognizes the limits of the evidence, recommends comparison with prior examinations, suggests follow-up, calls for clinical correlation, or identifies the need for escalation. AI systems intended for neuroradiological use must therefore be able to represent uncertainty in ways that are clinically meaningful, not merely statistically elegant. Their task should not be to appear confident in every situation, but to support safe decision-making when confidence is not justified.
This requirement becomes even more important because AI failure is scalable. A human error is usually confined to a specific encounter, shaped by local context and individual circumstances. A systematic computational failure, by contrast, can be reproduced across institutions, scanners, patient populations, and clinical workflows. This changes both the nature of risk and the standard of validation required before deployment. Average performance is not enough if errors accumulate in rare diseases, atypical presentations, pediatric cases, low-quality examinations, uncommon acquisition protocols, underrepresented populations, or emergency settings. In a field where rare findings may carry major consequences, AI must be stress-tested not only where clinical reality is common and predictable, but also where it is unstable, unusual, and dangerous.
Workflow is therefore not a secondary consideration, but one of the places where the clinical value of AI is actually determined. The same model may support or distort neuroradiological reasoning depending on how its output is introduced into the reading process. Presented too early, it may anchor interpretation before an independent assessment has formed; presented too late, it may add little to the decision; presented intrusively, it may increase cognitive load; presented without traceability, it may weaken accountability. AI should therefore be evaluated not only as a model, but as part of a human-machine interaction in which timing, visibility, interpretability, and responsibility shape its real effect on care.
This has direct consequences for neuroradiology. Triage algorithms may accelerate the recognition of urgent findings, but they must be designed to avoid false reassurance when the examination falls outside their reliable range. Segmentation tools may reduce repetitive work, but they must remain editable, transparent, and explicit about uncertainty. Quantitative platforms may generate increasingly sophisticated metrics, yet those metrics are clinically useful only when their reproducibility, scanner dependence, biological validity, and decision thresholds are understood. Structured reporting and AI-assisted documentation may improve consistency and reduce administrative burden, but they should not convert interpretation into the passive completion of predefined fields or the uncritical acceptance of generated text. The final report must remain a clinical act: a synthesis of imaging findings, context, uncertainty, and consequence.
Education is another domain in which the consequences of AI will be profound. The future of neuroradiology will depend not only on how experienced specialists incorporate intelligent systems into practice, but also on how trainees learn to think in their presence. The distinction between deskilling and never-skilling is particularly relevant. Deskilling refers to the gradual loss of a competence that has already been acquired; never-skilling refers to the possibility that a competence may never fully develop. A resident who repeatedly encounters automated segmentations, suggested diagnoses, generated reports, or machine-produced differential diagnoses before independently engaging with the image may become familiar with the conclusion without having learned the path that leads to it. The risk is therefore not only dependence on AI, but the formation of expertise that is technically supported and cognitively shallow. Neuroradiological judgment is built slowly, through exposure to normal anatomy, variants, artifacts, subtle abnormalities, false positives, false negatives, uncertainty, feedback, and clinical consequence. It requires the effort of constructing a differential diagnosis before receiving confirmation, and the discipline of comparing one’s interpretation with what the case later proves to be. AI can support this process if it is used as a scaffold for reasoning: a way to test hypotheses, reveal missed possibilities, challenge assumptions, and make uncertainty more explicit. Used prematurely as a shortcut to interpretation, however, it may weaken the very cognitive struggle through which judgment is formed.
For this reason, AI literacy in neuroradiology must mean more than technical familiarity with software. It must include the ability to interrogate AI outputs, to recognize when they are useful or incomplete, to detect when they may be biased or misleading, and to know when they should be subordinated to human clinical responsibility. The goal is not to train neuroradiologists who can simply operate intelligent systems, but to train physicians who remain intellectually independent in front of systems that are increasingly fluent, increasingly persuasive, and increasingly present in everyday practice.
Evidence must therefore become a central requirement. The field needs less fascination with isolated technical performance and more proof of clinical consequence. The relevant question is not simply whether an AI system reaches a high level of accuracy, but whether it improves care when placed inside real neuroradiological practice. Does it shorten time to treatment without increasing inappropriate activation? Does it improve diagnostic consistency without suppressing legitimate expert disagreement? Does it reduce workload without reducing attention? Does it support education rather than weaken the formation of judgment? Does it remain reliable across scanners, institutions, acquisition protocols, disease subtypes, and patient populations? These are not secondary questions. They are the conditions under which technical performance becomes clinical value.
At the same time, AI is entering neuroradiology precisely when the image itself is changing. Multiparametric MRI, vessel wall imaging, perfusion, diffusion, susceptibility imaging, spectroscopy, radiomics, connectomics, and molecularly informed approaches are all moving the field beyond visual description toward the characterization of measurable tissue states. In this context, AI may help extract hidden structure from increasingly complex data, but the interpretation of these signals will require more, not less, biological and clinical understanding. The neuroradiologist of the future may be less a describer of visible abnormalities and more an interpreter of disease processes quantified through imaging.
This is why the debate about replacement is too narrow. The more important question is not whether AI will replace neuroradiologists, but what kind of neuroradiology AI will help create. One possible future is faster but poorer: reports generated more quickly, patterns labeled automatically, and human judgment reduced to passive supervision. Another future is deeper: images become richer biological documents, uncertainty is made explicit, workflows become safer, and the neuroradiologist is supported in making more informed and responsible decisions.
The second future will not occur by itself. It will require governance, education, validation, and careful design. It will require collaboration among neuroradiologists, computer scientists, physicists, engineers, ethicists, regulators, patients, and health systems. It will require journals to publish not only promising algorithms, but rigorous studies of implementation, reproducibility, failure modes, bias, human factors, education, and clinical impact. It will require scientific societies to define standards and institutions to create environments in which AI is adopted not because it is fashionable, but because it is demonstrably useful, safe, and clinically meaningful.
Neuroradiology has always lived at the intersection of technology and meaning. CT changed the emergency evaluation of the brain. MRI transformed our understanding of white matter disease, tumors, inflammation, development, degeneration, and vascular pathology. Functional and molecular imaging changed the way we think about brain networks and biological activity. AI may become another transformation of this magnitude, but only if it is guided by clinical intelligence.
The future of neuroradiology will not be defined only by sharper images, faster algorithms, or more automated reports. It will be defined by our ability to transform data into understanding, predictions into decisions, measurements into meaning, and machine outputs into responsible care.
AI should help us see more. More importantly, it should help us think better.
And in neuroradiology, thinking better means preserving what has always been at the center of the discipline: the capacity to interpret the nervous system in all its complexity, uncertainty, vulnerability, and human consequence.